By Colin Kellaher


Immunogen has won U.S. Food and Drug Administration priority review for its application seeking to convert the accelerated approval of its cancer therapy Elahere to full approval.

The Waltham, Mass., pharmaceutical company on Tuesday said the FDA has set a target action date of April 5, 2024, for the application.

In November 2022, the FDA granted accelerated approval to Elahere for the treatment of patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

Elahere is the key asset in AbbVie's recent agreement to buy Immunogen for $10.1 billion.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

12-05-23 0731ET